[11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors

EJNMMI Research

Table 2 BP _ND of [ ¹¹ C]AF150(S) without and with pre-treatment with agents that increase extracellular levels of ACh

Brain region	Haloperidol		AF-DX 384		AF-DX 384 and rivastigmine
	(1 mg kg ⁻¹SC)		(5 mg kg ⁻¹IP)		(5 mg kg ⁻¹IP and 2.5 mg kg ⁻¹SC)
	Baseline	Pre-treated	Baseline	Pre-treated	Baseline	Pre-treated
Left striatum	0.23 ± 0.04	0.18 ± 0.01	0.27 ± 0.06	0.32 ± 0.04	0.25 ± 0.05	0.27 ± 0.03
Right striatum	0.28 ± 0.05	0.21 ± 0.03^*	0.30 ± 0.04	0.33 ± 0.05	0.23 ± 0.05	0.29 ± 0.03^*
Hippocampus	0.19 ± 0.02	0.16 ± 0.01^*	0.26 ± 0.04	0.26 ± 0.02	0.22 ± 0.02	0.25 ± 0.01^*
Frontal cortical area	0.10 ± 0.06	0.06 ± 0.04	0.24 ± 0.02	0.24 ± 0.06	0.17 ± 0.03	0.21 ± 0.02^**
Posterior cortical area	0.07 ± 0.07	0.06 ± 0.04	0.21 ± 0.03	0.22 ± 0.05	0.19 ± 0.04	0.19 ± 0.04

Data are presented as mean ± SD (n = 4 per group). SC, subcutaneous; IP, intraperitoneal. Significant difference compared with baseline: ^* p < 0.05, ^** p < 0.01.